RT Journal Article
SR Electronic
T1 Impact of SARS-CoV-2 infection on disease trajectory in youth with T1D: An EHR-based cohort study from the RECOVER program
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.03.22281916
DO 10.1101/2022.11.03.22281916
A1 Prahalad, Priya
A1 Lorman, Vitaly
A1 Wu, Qiong
A1 Razzaghi, Hanieh
A1 Chen, Yong
A1 Pajor, Nathan
A1 Case, Abigail
A1 Bose-Brill, Seuli
A1 Block, Jason
A1 Patel, Payal B
A1 Rao, Suchitra
A1 Mejias, Asuncion
A1 Forrest, Christopher B.
A1 Bailey, L. Charles
A1 Jhaveri, Ravi
A1 Thacker, Deepika
A1 Christakis, Dimitri A.
A1 Lee, Grace M.
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/11/05/2022.11.03.22281916.abstract
AB Background Post-acute sequelae of SARS-Co-V-2 infection (PASC) is associated with worsening diabetes trajectory. It is unknown whether PASC in children with type 1 diabetes (T1D) manifests as worsening diabetes trajectory.Objective To explore the association between SARS-CoV-2 infection (COVID-19) and T1D-related healthcare utilization (for diabetic ketoacidosis [DKA] or severe hypoglycemia [SH]) or Hemoglobin (Hb) A1c trajectory.Methods We included children <21 years with T1D and ≥1 HbA1c prior to cohort entry, which was defined as COVID-19 (positive diagnostic test or diagnosis code for COVID-19, multisystem inflammatory syndrome in children, or PASC) or a randomly selected negative test for those who were negative throughout the study period (Broad Cohort). A subset with ≥1 HbA1c value from 28-275 days after cohort entry (Narrow Cohort) was included in the trajectory analysis. Propensity score-based matched cohort design followed by weighted Cox regression was used to evaluate the association of COVID-19 with healthcare utilization ≥28 days after cohort entry. Generalized estimating equation models were used to measure change in HbA1c in the Narrow cohort.Results From 03/01/2020-06/22/2022, 2,404 and 1,221 youth met entry criteria for the Broad and Narrow cohorts, respectively. The hazard ratio for utilization was (HR 1.45 [95%CI,0.97,2.16]). In the Narrow Cohort, the rate of change (slope) of HbA1c increased 91-180 days after cohort entry for those with COVID-19 (0.138 vs. -0.002, p=0.172). Beyond 180 days, greater declines in HbA1c were observed in the positive cohort (-0.104 vs. 0.008 per month, p=0.024).Conclusion While a trend towards worse outcomes following COVID-19 in T1D patients was observed, these findings were not statistically significant. Continued clinical monitoring of youth with T1D following COVID-19 is warranted.Authorship Statement Authorship has been determined according to ICMJE recommendationsDisclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH or other funders.Funding Source ⍰This research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research.Competing Interest StatementDr Brill received support from Novartis and Regeneron Pharmaceuticals within in the last year Dr. Chen receives consulting support from GSK. Dr. Patel reports funding from the National Institute of Health and Bayer Pharmaceuticals Dr. Rao reports prior grant support from GSK and Biofire and is a consultant for Sequiris. Dr. Mejias reports funding from Janssen and Merck for research support; Janssen, Merck and Sanofi-Pasteur for Advisory Board participation, and Sanofi-Pasteru and AstraZeneca for CME lectures. Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial stipend from Elsevier and Pediatric Infectious Diseases Society and royalties from Up To Date/Wolters Kluwer. Dr. Lee serves on the PASC Advisory Board for United Health Group. Funding StatementThis research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Childrens Hospital of Philadelphia Institutional Review Board designated this study as not human subjects research and waived informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors